Skip to main content

Edesa Biotech, Inc.

For the period ended Sep 30, 2025. Filed Dec 12, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Dec 12, 2025

EDSA$2.02-18.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

24.1 Power of Attorney (included on signature page)

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pardeep Nijhawan and Peter Weiler, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated

SignatureTitleDate
/s/ Pardeep NijhawanDirector, Chief Executive Officer, andDecember 12, 2025
Pardeep NijhawanCorporate Secretary (Principal Executive Officer)
/s/ Peter WeilerChief Financial OfficerDecember 12, 2025
Peter Weiler(Principal Financial and Accounting Officer)
/s/ Joan ChypyhaDirectorDecember 12, 2025
Joan Chypyha
/s/ David LiuDirectorDecember 12, 2025
David Liu
/s/ Sean MacDonaldDirectorDecember 12, 2025
Sean MacDonald
/s/ Patrick MarshallDirectorDecember 12, 2025
Patrick Marshall
/s/ Charles OlsonDirectorDecember 12, 2025
Charles Olson
/s/ Carlo SistilliChairman of the Board of DirectorsDecember 12, 2025
Carlo Sistilli

INDEX TO FINANCIAL STATEMENTS

Page
Report of Independent Registered Public Accounting Firm – MNP LLP, Toronto Canada, PCAOB ID 1930F-2
Consolidated Balance Sheets at September 30, 2025 and 2024F-4
Consolidated Statements of Operations and Comprehensive Loss for the years ended September 30, 2025 and 2024F-5
Consolidated Statements of Cash Flows for the years ended September 30, 2025 and 2024F-6
Consolidated Statements of Changes in Shareholders’ Equity for the years ended September 30, 2025 and 2024F-7
Notes to Consolidated Financial StatementsF-8
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.